Disease

Platform

Product name

Biomarker

Significant finding

Sample type

Sampel size

Reference

Ovarian Cancer

Glass slides-label based antibody array

RayBiotech L-507

Screening marker

Five proteins, including IL-2 receptor alpha, endothelin, osteprotegerin, vascular endothelial growth factor D (VEGF-D) and betacellulin (BTC) were identified to distinguish ovarian cancer from healthy controls.

Serum

serum samples from 47 patients with ovarian cancers, 33 patients with benign ovarian masses and 39 healthy, age-matched controls

(15)

Breast Cancer

Nitrocellulose membranes-sandwitch-based antibody array

RayBiotech Human Cytokine Array III C-series

pre-clinical studies

4 4 biomarkers were identified with increased expression in MCF-7/Her2-18 cells (CXCL8, IL8, CXCL1, and GRO)

Cultural  Media

Her-2 overexpressed cell line MCF-7/Her2-18 and parental cell line MCF-7/neo cell line

(27)

Breast Cancer

Glass slides-label-based antibody array

In house custom production

efficacy markers

A panel of 4 proteins (AP-2, catalase, thymidylate synthase, and ErbB2) was higher in MDA-MB-231 cells compared with control cells

Cell Lysates

THP cell line exposed to different drug delivery systems, including amphotericin B (AMB), Fungizone (FZ) and Amphotec (ABCD),and controls AmBisome (L-AMB) or Abelcet (ABLC)

(25)

Breast Cancer

Glass slides-label-based antibody array

The BD antibody microarray 380

pre-clinical studies

A panel of protein markers were identified to distinguish malignant and adjacent normal breast tissue in a patient with primary breast cancer, including casein kinase Ie, p53, annexin XI, CDC25C, eIF-4E and MAP kinase 7 and 14-3-3e.

Tissue Lysates

Normal and malignant breast tissue was obtained from a 54-year-old consenting post-menopausal patient undergoing modified mastectomy for early breast cancer

(24)

Breast Cancer

Glass slides-label-based antibody array

In house custom production

Prognosis marker

A panel of 21 protein markers were identified to distingusih high-vs-low-risk groups for development of distant metastatic breast cancers

Serum

240 sera samples from 64 primary breast cancer patients, which were collected at the primary operation and then 3-6 month later

(29)

Brain Tumor

Glass slides-label-based antibody array

In house custom production

Prognosis marker

A 15-marker panel was identified to classification of GBM patients into long-term survival vs short-term survival group

Serum

serum samples from 18 GM patients and 17 healthy controls

(32)

Colorectal Cancer( CRC )

Glass slides-label-based antibody array

RayBiotech L-507

treatment monitoring marker

58 and 47 proteins identified with significant modulation at post vaccination of month 2 and 4, compared with prevaccination

plasma

14 samples from 18 patients with prevaccination, post vaccination month 2 and month 4

(31)

Prostate Cancer

Nitrocellulose membranes-sandwitch-based antibody array

RayBiotech Human Cytokine ArrayC-series 2000

pre-clinical studies

MCP-1 and IL-8 was highly expressed in all prostate cancer cell lines compared with control cell line. In addition, Levels of GRO-alpha were greater in LNCaP, C4-2B and PC3 cells compared with PrEC cells, Levels of VEGF, CXCL-16 and MMP-9 were greater in PC3 cells compared with PrEC cells

Cultural Media

4 different prosate cancer cell lines ( LNCaP, C4-2B, PC3, A549) and prostate cell line PrEC.

(30)

Bladder Cancer

Glass slides-RCA antibody array

In house custom production

screening marker

Serum protein profiles measured by an antibody array containing 254 antibodies discriminated bladder cancer patients from controls (n _ 95) with a correct classification rate of 93.7%. A second independent antibody array containing 144 antibodies revealed that protein profiles provide predictive information by stratifying patients with bladder tumors (n _ 37) based on their overall survival (P<0.05)

Serum

SerumSerum samples from 95 individuals representing 58 controls and 37 patients with bladder cancer

(34)

Pancreatic Cancer

Glass slides-RCA antibody array

In house custom production

screening marker

 

Serum

One hundred forty-two serum samples were used from three classes: healthy subjects (n = 50), pancreatic adenocarcinoma patients (n = 61), and patients with benign pancreatic diseases (n = 31)

(37)

Pancreatic Cancer

Glass slides-label-based antibody array

In house custom production

screening and prognosis marker

 

Serum

serum samples from 24 pancreatic cancer patients and 20 healthy controls

(33)

Leaukemia

Nitrocellulose membranes-sandwitch-based antibody array

RayBiotech Human Cytokine Array

efficacy markers

 

Culture Media

THP cell line exposed to different drug delivery systems, including amphotericin B (AMB), Fungizone (FZ) and Amphotec (ABCD),and controls AmBisome (L-AMB) or Abelcet (ABLC)

(36)

Table 1: Summary of cancer-related biomarker discoveries using planar form of antibody arrays.